Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): A multicenter randomised controlled study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Van de Laar, Rafli ^a   Zusterzeel, Petra L M ^a   Van Gorp, Toon ^b   Buist, Marrije R ^c   Van Driel, Willemien J ^d   Gaarenstroom, Katja N ^e   Arts, Henriette J G ^f   Van Huisseling, Johannes C M ^g   Hermans, Ralph H M ^h   Pijnenborg, Johanna M A ⁱ   Schutter, Eltjo M J ^j   Pelikan, Harold M P ^k   Vollebergh, Jos H A ^l   Engelen, Mirjam J A ^m   IntHout, Joanna ^a   Kruitwagen, Roy F P M ^b   Massuger, Leon F A G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g GROENE HART HOSPITAL   (Netherlands)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^j MEDISCH SPECTRUM TWENTE   (Netherlands)

^k MEDICAL CENTER HAAGLANDEN   (Netherlands)

^l BERNHOVEN HOSPITAL   (Netherlands)

^m Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

Ovarian cancer; Platinum sensitive; Recurrent; Secondary cytoreductive surgery

Indexed keywords

PLATINUM;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PATIENT MONITORING; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE; UTERINE TUBE TUMOR; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; OVARIECTOMY; PLATINUM COMPOUNDS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892380764     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-22     Document Type: Article

References (13)

1. Ledermann JA, Raja FA. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer 2011, 47:S104-S115.
2. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-2106.
3. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005, 15(Suppl 1):36-41.
4. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30(17):2039-2045. 10.1200/JCO.2012.42.0505, 3646321, 22529265.
5. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009, 112(1):265-274. 10.1016/j.ygyno.2008.08.033, 18937969.
6. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006, 13(12):1702-1710. 10.1245/s10434-006-9058-0, 17009163.
7. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011, 21(2):289-295. 10.1097/IGC.0b013e31820aaafd, 21270612.
8. Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012, 19(2):597-604. 10.1245/s10434-011-1873-2, 21732142.
9. Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010, 36(6):583-588. 10.1016/j.ejso.2010.04.012, 20488646.
10. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2010, 6. CD007822.
11. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade- Lauraine E, Sehouli J, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011, 21(4):771-775. 10.1097/IGC.0b013e31821bb8aa, 21543939.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
13. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011, 21(2):419-423. 10.1097/IGC.0b013e3182070f17, 21270624.